<SEC-DOCUMENT>0001213900-25-065728.txt : 20250718
<SEC-HEADER>0001213900-25-065728.hdr.sgml : 20250718
<ACCEPTANCE-DATETIME>20250718170417
ACCESSION NUMBER:		0001213900-25-065728
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240208
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250718
DATE AS OF CHANGE:		20250718

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		251135110

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>ea0249475-8ka_abvcbio.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ABVC="http://abvcpharma.com/20240208">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_ABVC_abvcpharma.com_20240208 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20240208_20240208 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20240208.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-08</xbrli:startDate>
        <xbrli:endDate>2024-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20240208__20240208_z9wVJAAcyBu7"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000009" name="dei:DocumentType">8-K/A</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
July 18, 2025 (<span id="xdx_908_edei--DocumentPeriodEndDate_c20240208__20240208_zaKuA5vYTJeb"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">February 8, 2024</ix:nonNumeric></span>)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20240208__20240208_z2yrR5kvBn0i"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000011" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20240208__20240208_zdhOJGCluMwc"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20240208__20240208_zlyLXoZgqix7"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000013" name="dei:EntityFileNumber">001-40700</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20240208__20240208_zbuqtghs7Vsg"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20240208__20240208_zCaZ9Iiu3fkj"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000015" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20240208__20240208_zYA5rRcix3I5"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000016" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20240208__20240208_zbSMNLjJub88"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000017" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20240208__20240208_zjXvZh96OlI"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000018" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_90C_edei--CityAreaCode_c20240208__20240208_zQfhLRv2lsh2"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000019" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20240208__20240208_zsvW5f7eDl6b"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000020" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--WrittenCommunications_c20240208__20240208_z3UWiLc7jU49"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SolicitingMaterial_c20240208__20240208_zXC1cCGnm1T5"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20240208__20240208_zqGOuVub5dE1"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20240208__20240208_zxqXSpywLbc9"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Each Class</span></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</span></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20240208__20240208_zjKbpwjQBuj7"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20240208__20240208_zHTxAWzQz7g2"><ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000026" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20240208__20240208_zvUsVBsUukEc"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20240208__20240208_zYIkQSqkmFy7"><ix:nonNumeric contextRef="AsOf2024-02-08" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into Material Definitive Agreements</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<div id="xdx_98E_edei--AmendmentDescription_c20240208__20240208_zMf9lSlnEvy9">

<ix:nonNumeric contextRef="AsOf2024-02-08" id="Fact000029" name="dei:AmendmentDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously reported,
on February 6, 2024, ABVC BioPharma, Inc. (the &#8220;<b>Company</b>&#8221;) reported that it entered into a definitive agreement
with Shuling Jiang (&#8220;<b>Jiang</b>&#8221;), pursuant to which Jiang shall transfer the ownership of certain land she owns
located at Taoyuan City, Taiwan (the &#8220;<b>Land</b>&#8221;) to the Company (the &#8220;<b>Original Agreement</b>&#8221;). Jiang
is a director of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Office and currently owns approximately
8.16% of the Company&#8217;s issued and outstanding shares of the Company&#8217;s common stock, par value, $0.001 per share (the
&#8220;<b>Comon Stock</b>&#8221;). Accordingly, the transaction contemplated by the Agreement constitutes a related party
transaction as defined by Item&#160;404&#160;of&#160;Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As later reported, on
May 16, 2024, the Company&#8217;s board of directors determined that it was in the best interest of the Company and its shareholders
to terminate the Agreement and not proceed with the transfer of land ownership at such time and that it may later reconsider the
transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As disclosed in the Proxy
Statement (the &#8220;<b>Proxy</b>&#8221;) for the Company&#8217;s 2025 Annual Shareholder Meeting (the &#8220;<b>Meeting</b>&#8221;)
held on June 3, 2025 (the &#8220;<b>Meeting Date</b>&#8221;), <span style="background-color: white">the Company and Jiang were renegotiating
the terms of the Shuling Transaction. The Proxy also stated that </span>consideration for the Land would be consist of a combination of
shares of our common stock (the &#8220;<b>Jiang Shares</b>&#8221;) and warrants to purchase shares of common stock (&#8220;<b>Warrants</b>&#8221;),
but since the number of Jiang Shares was uncertain and therefore possible that it would result in the issuance of an amount of shares
of common stock equal to or in excess of 20% of our common stock outstanding at a price that is less than the Minimum Price (as hereinafter
defined), we determined to obtain shareholder approval of the issuance pursuant to Nasdaq Listing Rule&#160;5635(d). The Company obtained
the required shareholder approval at the Meeting. On July 15, 2025, the parties entered into definitive agreements for the Land (the &#8220;<b>Definitive
Agreement</b>&#8221;), which includes a warrant agreement (the &#8220;<b>Warrant</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Definitive
Agreement, the Company shall issue (i) 2,035,136 Jiang Shares, which is based on the closing price of the Company&#8217;s common stock
on the Meeting Date and a land valuation of $3,857,975<sup>1</sup> and (ii) a Warrant to purchase up to 1,000,000 shares of the Company&#8217;s
common stock at an exercise price of $2.50 per share; following which, Jiang shall transfer ownership of the Land to the Company. Additionally,
if the Company voluntary delists from the Nasdaq Capital Market and does not list its common stock on another national exchange or there
is a change of control, Jiang maintains the right to have the title of the Land returned to her, subject to her return of all un-exercised
Warrants and any Jiang Shares that she has not transferred or sold prior thereto. Shuling also remains eligible to receive additional
shares of the Company&#8217;s common stock if the price of the Company&#8217;s common stock falls below $1.65 per share during any six-month
period prior to the time the Jiang Shares may be sold without restriction and she does not prefer to have the title returned to her.
Should she choose to receive additional shares, the number of shares issuable shall be based on the lowest closing price during such
six-month period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
Warrant has a term of 5 years and may be exercised via cashless exercise. A holder (together with its affiliates) may not exercise any
portion of such holder&#8217;s Warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately
after exercise (the &#8220;<b>Maximum Percentage</b>&#160;&#8221;), except that if at any time the Holder Group (as defined in the Warrant)
beneficially owns in excess of 4.99% of any class of equity interests in the Company that is registered under the Securities Exchange
Act of 1934, as amended (excluding any interests deemed beneficially owned by virtue of the Warrant), then the Maximum Percentage shall
automatically increase to 9.99% so long as the Holder Group owns in excess of 4.99% of such class of equity interests (and shall, for
the avoidance of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to own in excess of 4.99% of such class of equity
interests) (the &#8220;<b><span style="text-decoration: underline">Beneficial Ownership Limitation</span></b>&#8221;).<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">As part of the Definitive Agreement,
the parties also entered into a consulting agreement, pursuant to which Jiang shall help with the development and maintenance of the Land
(the &#8220;<b>Consulting Agreement</b>&#8221;). For such services, Jiang shall receive $1,000,000 to be paid in 1,000,000 shares of the
Company&#8217;s common stock, subject to a five-year vesting schedule at the rate of 200,000 shares per year. The Consulting Agreement
has a 1-year term, unless terminated earlier by either party upon 30 days prior written notice. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="vertical-align: top; width: 15pt; text-align: left"><sup>1</sup></td><td style="width: 5pt"/><td style="text-align: justify">The Definitive Agreement attached hereto as Exhibit 10.1 contains a typo. The gross value
of the Property is actually estimated to be US$3,857,975.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the issuance of the Jiang Shares, Jiang shall own approximately
16.5% of the Company&#8217;s issued and outstanding shares of Common Stock. Assuming all the Warrants are exercised at the exercise price,
she will own a total of approximately 20.1% of the Company&#8217;s issued and outstanding shares of Common Stock as of the date hereof.
Assuming we issue all of the shares issuable pursuant to the Consulting Agreement, she will own a total of approximately 23.3% of the
Company&#8217;s issued and outstanding shares of Common Stock as of the date hereof. The prior percentages ignore all beneficial ownership
caps and vesting schedules, to show Jiang&#8217;s total potential ownership.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Definitive Agreement also contains customary termination provisions, and other obligations and rights of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Definitive Agreement, Warrant and Consulting Agreement is qualified by reference to the full text of such documents, which are
filed as exhibits hereto and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
above under Item 1.01, to the extent applicable, is hereby incorporated by reference herein. The issuance of the Jiang Shares and warrants
pursuant to the Agreement was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended
(the &#8220;<b>Securities Act</b>&#8221;), and Regulation S under the Securities Act and corresponding provisions of state securities
or &#8220;blue sky&#8221; laws. None of the securities have been registered under the Securities Act or any state securities laws and
may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements.
The sale of the securities did not involve a public offering and was made without general solicitation or general advertising.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither this Current Report
on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein.
Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company&#8217;s
securities in any state in which such an offer, solicitation or sale would be unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Exhibits </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea024947501ex4-1_abvcbio.htm">Form of Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><a href="ea024947501ex10-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: none">Agreement between the Company and </span>Shuling Jiang</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><a href="ea024947501ex10-2_abvcbio.htm">Consulting Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File, formatted in Inline XBRL</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 34%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 18, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>












<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5LvYhWuynRUWsUkoRfwcbZbCdlMz4WpK7dNoihkBI7j25QvhiQ2vVIMNpWeZQYds10iKUeEFGfUbnyLa7FNws8aqMZantsP7AjByDjplPIunug/OhDNYphEkQJUE8g3CeThdQ7IXX6xnpi6pRWyUbkLqGgqljhVbye/xQyRdpat9D0hHZKNIpRJNwlD8Qh1EMB3rIJ/HNQJ5nwvOH8sSG6d451+plUfckrBpsXZwZ6X97X9JvSmg= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea024947501ex4-1_abvcbio.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This WARRANT AGREEMENT (this &ldquo;Agreement&rdquo;) is entered into as of July 15, 2025 (the &ldquo;Issue Date&rdquo;), by and between ABVC
BioPharma, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), and Shuling Jiang (the &ldquo;Holder&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement is issued pursuant to that certain Definitive Land Purchase Agreement between the Company and the Holder dated July 15,
2025 (the &ldquo;Land Agreement&rdquo;).<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Grant of Warrant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company hereby grants to the Holder a warrant
(the &ldquo;Warrant&rdquo;) to purchase 1,000,000 shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;),
at an exercise price of $2.50 per share (the &ldquo;Exercise Price&rdquo;), subject to the cashless exercise provision detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Term of Warrant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant shall be exercisable at any time beginning
on the date of issuance and ending at 5:00 PM New York time on the fifth (5th) anniversary of the Issue Date (the &ldquo;Expiration Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Cashless Exercise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In lieu of exercising this Warrant for cash, the
Holder may elect to receive shares of Common Stock equal to the value of this Warrant (or the portion thereof being exercised) by surrendering
this Warrant with written notice of such election, in which event the Company shall issue to the Holder a number of shares of Common Stock
computed using the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[ X = Y &times; (A - B) / A ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- X = the number of shares of Common Stock to be issued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Y = the number of shares with respect to which the Warrant is being exercised</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- A = the Market Value of one share of Common Stock on the date of exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- B = the Exercise Price of $2.50</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Market Value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Agreement, &ldquo;Market Value&rdquo;
shall mean the closing sale price of the Common Stock on NASDAQ (or the principal trading market for the Company&rsquo;s Common Stock)
on the last trading day before the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. Adjustment Provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of Common Stock issuable
upon exercise and/or the Exercise Price are subject to adjustment in accordance with standard anti-dilution protections, including stock
splits, combinations, dividends, or reorganizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. Governing Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall be governed by and construed
in accordance with the laws of the State of New York, without giving effect to conflict of law principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. No Rights as Shareholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant does not entitle the Holder to any
rights as a shareholder of the Company until such time as the Warrant is exercised and shares are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify">8.
Limitations on Exercises.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Notwithstanding anything to
the contrary contained herein, the Holder shall not be entitled to receive shares of Common Stock or other securities (together with Common
Stock, &ldquo;<U>Equity Interests</U>&rdquo;) upon exercise of this Warrant to the extent (but only to the extent) that such exercise
or receipt would cause the Holder Group to become, directly or indirectly, a &ldquo;beneficial owner&rdquo; (within the meaning of Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder) of a number of Equity Interests of a class that is registered
under the Exchange Act which exceeds the Maximum Percentage (as defined below) of the Equity Interests of such class that are outstanding
at such time. Any purported delivery of Equity Interests in connection with the exercise of the Warrant prior to the termination of this
restriction in accordance herewith shall be void and have no effect to the extent (but only to the extent) that such delivery would result
in the Holder Group becoming the beneficial owner of more than the Maximum Percentage of the Equity Interests of a class that is registered
under the Exchange Act that is outstanding at such time. If any delivery of Equity Interests owed to the Holder following exercise of
this Warrant is not made, in whole or in part, as a result of this limitation, the Company&rsquo;s obligation to make such delivery shall
not be extinguished and the Company shall deliver such Equity Interests as promptly as practicable after the Holder gives notice to the
Company that such delivery would not result in such limitation being triggered or upon termination of the restriction in accordance with
the terms hereof. To the extent limitations contained in this <U>Section 8</U> apply, the determination of whether this Warrant is exercisable
and of which portion of this Warrant is exercisable shall be the sole responsibility and in the sole determination of the Holder, and
the submission of an Exercise Notice shall be deemed to constitute the Holder&rsquo;s determination that the issuance of the full number
of Warrant Shares requested in the Exercise Notice is permitted hereunder, and neither the Company nor any Warrant agent shall have any
obligation to verify or confirm the accuracy of such determination. For purposes of this <U>Section 8</U>, (i) the term &ldquo;<U>Maximum
Percentage</U>&rdquo; shall mean 4.99%; provided, that if at any time after the date hereof the Holder Group beneficially owns in excess
of 4.99% of any class of Equity Interests in the Company that is registered under the Exchange Act (excluding any Equity Interests deemed
beneficially owned by virtue of this Warrant), then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder
Group owns in excess of 4.99% of such class of Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99%
upon the Holder Group ceasing to own in excess of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder Group</U>&rdquo;
shall mean the Holder plus any other Person with which the Holder is considered to be part of a group under Section 13 of the Exchange
Act or with which the Holder otherwise files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity
Interests of a particular class outstanding at any point in time, the Holder may rely on the number of outstanding Equity Interests of
such class as reflected in (x) the Company&rsquo;s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, as the case may be, (y) a more recent public announcement by the Company or (z) a more recent
notice by the Company or its transfer agent to the Holder setting forth the number of Equity Interests of such class then outstanding.
For any reason at any time, upon written or oral request of the Holder, the Company shall, within one (1) Trading Day of such request,
confirm orally and in writing to the Holder the number of Equity Interests of any class then outstanding. The provisions of this <U>Section
8</U> shall be construed, corrected and implemented in a manner so as to effectuate the intended beneficial ownership limitation herein
contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Company has caused this
Warrant Agreement to be executed by its duly authorized officer as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC BioPharma, Inc.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#34083;&#28113;&#40801;
    Shuling Jiang</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signature/Seal</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signature/Seal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name&#65306;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Uttam Yashwant Patil</I></FONT></TD>
    <TD STYLE="text-align: justify; width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name&#65306;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shuling Jiang</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Land Owner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea024947501ex10-1_abvcbio.htm
<DESCRIPTION>DEFINITIVE AGREEMENT BETWEEN THE COMPANY AND SHULING JIANG
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="background-color: #F7F7F8"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: #F7F7F8">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>Definitive
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This Definitive
Agreement (</FONT>&ldquo;<U>Agreement</U>&rdquo;<FONT STYLE="background-color: white">) is entered into as of July 15, 2025, by and between
</FONT>ABVC BioPharma, Inc. (&ldquo;<U>ABVC</U>&rdquo;)<FONT STYLE="background-color: white">, and </FONT>Shuling Jiang (hereinafter referred
to as &ldquo;<U>Shuling</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">ABVC and
</FONT>Shuling <FONT STYLE="background-color: white">are sometimes referred to herein individually as a </FONT>&ldquo;<U>Party</U><FONT STYLE="background-color: white">,</FONT>&rdquo;
<FONT STYLE="background-color: white">and collectively as the </FONT>&ldquo;<U>Parties</U><FONT STYLE="background-color: white">.</FONT>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to strategically cooperate and construct an
integrated platform for the global development of the healthcare business and the medical, pharmaceutical, and biotechnology in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 1: Subject Matter and Consideration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.1</TD><TD STYLE="text-align: justify">Subject Matter: The subject matter of this Agreement includes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) The common shares of ABVC (stock symbol: ABVC)
listed on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) Shuling&rsquo;s ownership of a property located at
Taoyuan City, Taiwan (hereinafter referred to as The Land or The Property).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.2</TD><TD STYLE="text-align: justify">Consideration: The consideration for this Agreement shall be as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)
ABVC shall issue 2,035,136 restricted common shares to Shuling Jiang as consideration for the Property, based on the June 3, 2025, closing
share price of $1.65, as approved in the shareholder meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">b)
</FONT>ABVC agrees to issue 1,000,000 cashless warrants to Shuling Jiang, with an exercise price of US$2.50 per share, exercisable on
a net-share settlement basis as defined in the warrant agreement<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c) Shuling Jiang shall transfer the NT$15,000,000
or US$500,000 bank liability of the land to ABVC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d) Shuling Jiang shall transfer ownership of The
Land to ABVC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.3 Transfer of Ownership: Upon completion of
the transaction, ownership of the ABVC Shares shall be transferred from ABVC to Shuling, and ownership of The Land shall be transferred
from Shuling to ABVC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants to be issued shall be structured
as &ldquo;cashless exercise warrants,&rdquo; whereby upon exercise, Shuling shall receive the number of shares equal to the in-the-money
value of the warrants without payment of cash, determined using the formula:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Shares = (A - B) / A &times; Number of Warrants Exercised</B>,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">where A = Market Value at time of exercise, and B = Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 2: Exchange of The Land through ABVC
Equity Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.1 Agreement to Exchange The Land: ABVC and Shuling
agree to exchange ownership in Shuling&rsquo;s real estate The Land through an equity transfer of ABVC shares. The gross value of the Property
is estimated to be US$3,800,000, as determined by prior land valuation reports and supported by the intended use for rehabilitation center
development. After deducting the estimated bank loan liability of US$500,000 assumed by ABVC, the net acquisition value is US$3,300,000.
This amount is to be satisfied through the issuance of restricted shares and warrants, as approved by the shareholders on June 3, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.2 Value of the Exchange: The value of the exchange
is estimated to be US$3.36 million, which includes the issuance of 2,035,136 restricted shares of ABVC common stock based on the approved
pricing methodology from the shareholder meeting. This reflects the June 3, 2025, closing price of $1.65 per share and assumption of a
$500,000 bank liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.3 Transfer Process: The transfer of ABVC Shares
from ABVC to Shuling shall be executed in accordance with the applicable laws, regulations, and procedures governing equity transfers,
as well as Regulation S promulgated under the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.4 Transfer of Ownership: Upon completion of
the equity transfer, the ownership stake in Shuling&rsquo;s real estate The Property shall be transferred from Shuling to ABVC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.5 Representation of Value: Both parties acknowledge
and agree that the value of the exchange is based on the estimated value of The Property and the market value of ABVC shares at the time
of the equity transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.6 Valuation Dispute: In the event of any dispute
regarding the valuation or other matters related to the exchange, the parties shall make good faith efforts to resolve the dispute through
negotiation and mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.7 Taxes and Fees: Any taxes, fees, or other
charges arising from the equity transfer and exchange shall be the responsibility of the respective parties as determined by applicable
laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 3: Capital Protection Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.1 Valuation Assessment: In the event of a dispute
regarding the valuation or value maintenance, the parties may engage an independent third-party expert or appraiser to assess the value
and provide recommendations for adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.2 Amendments to the Agreement: Any amendments
or modifications to the definitive agreement necessitated by the value adjustment shall be made in writing and signed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.3 Force Majeure: The provisions of the definitive
agreement shall not apply in cases of force majeure events that are beyond the reasonable control of either party and that significantly
impact the value of The Land or stocks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.4 Governing Law and Jurisdiction: This Agreement
shall be governed by and construed in accordance with the laws of the jurisdiction in the State of New York. Any disputes arising from
or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 4: Termination, Replacement and Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.1 Both parties aim to complete the transfer
of the target assets by July 15, 2025. If unable to do so, both parties shall negotiate and determine a subsequent transfer date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2 Composition: Supplementary agreements or appended
documents related to assets and equity transfer subsequently signed by both parties shall constitute valid integral parts of this Agreement.
The rights and obligations of both parties shall be subject to the terms and conditions stipulated in this agreement and in any supplementary
agreements or appended documents subsequently signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.3 Amendment: The terms and conditions in this
Agreement can be further amended in writing upon the mutual agreement of both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.4 Termination: This Agreement may be terminated
by mutual written consent of both parties and in the event of a material breach by either party that is not cured within a reasonable
period after written notice. Upon termination, the provisions of Articles 4, 5, and 6 shall survive and continue in full force and effect
to the extent necessary to give effect to the rights and obligations accrued prior to termination, or where expressly stated to survive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.5: Reversion Right upon Delisting or Change
of Control</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that (a) ABVC BioPharma, Inc. is
involuntarily delisted from the Nasdaq Capital Market and fails to relist on a national securities exchange, or (b) a Change of Control
of ABVC occurs, then Shuling Jiang shall have the right to request a re-transfer of the title of the Property to her name, subject to
the return of all unexercised warrants and any remaining shares not transferred or sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this clause, &ldquo;Change of
Control&rdquo; shall mean any (i) merger or consolidation of ABVC with or into another entity, (ii) sale or transfer of all or substantially
all of ABVC&rsquo;s assets, or (iii) acquisition by any person or entity of more than twenty percent (20%) of ABVC&rsquo;s voting equity
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such reversion right shall be subject to applicable
law, and the Parties agree to cooperate in good faith to effectuate such reversion, including through execution of necessary documents
and filings with the relevant authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the ABVC stock price falls below $1.65 at any
point during the 6 months immediately preceding the date the restricted shares become eligible for trading, Shuling Jiang shall be entitled
to receive additional ABVC common shares to compensate for the shortfall. The number of shares shall be based on the lowest closing price
during that 6-month period, ensuring the originally agreed value is preserved. Alternatively, Shuling may exercise the reversion right
defined above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 5: Confidentiality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.1 Duty of Care: Both parties agree to exercise
due care in maintaining the confidentiality of any relevant data or information. This duty of confidentiality shall not be affected by
the termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.2 Non-Disclosure Obligation: Both parties shall
keep all confidential information received from the other party confidential and shall not disclose it to any third party without prior
written consent, unless required by law or authorized by the disclosing party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.3 Return or Destruction of Confidential Information:
Upon the expiration, termination, or at the request of either party, the receiving party shall promptly return to the disclosing party
all confidential information received, along with any copies or reproductions thereof. Alternatively, the receiving party shall follow
the instructions of the disclosing party regarding the destruction of such confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.4 Survival of Confidentiality Obligations: The
obligations of confidentiality and non-disclosure shall survive the expiration or termination of this Agreement and shall continue to
be binding on both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.5 Exceptions: The obligations of confidentiality
shall not apply to information that: (a) was already known to the receiving party prior to its disclosure by the disclosing party; (b)
is or becomes publicly available without breach of this Agreement; (c) is received from a third party without breach of any confidentiality
obligation; or (d) is independently developed by the receiving party without reference to the disclosing party&rsquo;s confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 6: Copies of the Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.1 Two original copies of this Agreement have
been prepared, with each party holding one original copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.2 After signing, each party shall retain the
original copy held by them as valid evidence between the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.3 Copies, reproductions, or electronic files
of this Agreement shall have the same legal effect and may be used for communication between the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 7: Subcontract Consulting Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to this land acquisition transaction,
the Parties acknowledge that ABVC and Shuling Jiang shall enter into a separate consulting agreement regarding the development and maintenance
of The Property. This agreement shall include compensation valued at $1,000,000, to be issued as 1,000,000 ABVC restricted shares, subject
to a 5-year vesting schedule of 200,000 shares per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties acknowledge that the number of securities
issued reflects the mutually agreed commercial value of the transaction and is subject to appropriate fair value determination for accounting
purposes. This does not alter the number of shares or warrants to be issued as agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC BioPharma, Inc.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#34083;&#28113;&#40801;
    Shuling Jiang</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signature/Seal</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signature/Seal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name&#65306;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Uttam Yashwant Patil</I></FONT></TD>
    <TD STYLE="text-align: justify; width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name&#65306;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shuling Jiang</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Land Owner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea024947501ex10-2_abvcbio.htm
<DESCRIPTION>CONSULTING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Consulting Agreement (&ldquo;Agreement&rdquo;) is made and entered
into as of July 15, 2025, by and between ABVC BioPharma, Inc., a Nevada corporation (&ldquo;Company&rdquo;), and Shuling Jiang (&ldquo;Consultant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, the Company desires to engage Consultant to provide certain
land-related consulting services as described herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, Consultant possesses the qualifications, knowledge, and experience
to provide such services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE, in consideration of the mutual covenants and promises
contained herein, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Scope of Services</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consultant shall provide advisory and development support services
related to the Company&rsquo;s land located in Shulin, Taoyuan, Taiwan. Such services include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Site supervision and care</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Coordination of maintenance activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Liaison with local authorities regarding land zoning and permits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Participation in early-stage development planning</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Oversight of site development planning in alignment with rehabilitation
center goals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Reporting to ABVC board on quarterly site progress and regulatory
status</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Acting as ABVC&rsquo;s land liaison to government agencies in Taiwan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As full and complete compensation for the services rendered under this
Agreement, the Company shall issue to Consultant the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1,000,000 restricted shares of Company common stock, subject to a 5-year vesting schedule of 200,000 shares per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No additional warrants shall be issued under this agreement.The issuance of shares and warrants shall be subject to Board approval and compliance with applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Term and Termination</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement shall commence on the Effective Date and continue for
a period of 12 months unless earlier terminated by either party upon thirty (30) days&rsquo; prior written notice. Upon termination, Consultant
shall return all Company property and cease representation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. Confidentiality</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consultant agrees to maintain in confidence all non-public information
obtained during the course of services and shall not disclose such information to any third party without prior written consent of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. Independent Contractor</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consultant shall act solely as an independent contractor. Nothing herein
shall be construed to create a partnership, joint venture, or employment relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. Tax Responsibilities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consultant acknowledges and agrees that any shares and warrants issued
may be treated as compensation for services and could be subject to U.S. federal income tax reporting under Section 83 of the Internal
Revenue Code. Consultant shall be solely responsible for all taxes arising from any compensation received hereunder. The Company shall
not withhold any taxes unless required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consultant acknowledges the vesting schedule is intended to reduce
upfront tax burden under Section 83 and agrees to consult independent tax advisors on any elections or filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. Governing Law</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement shall be governed by and construed in accordance with
the laws of the State of New York, without regard to its conflict of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Signature Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties acknowledge that the number of securities
issued reflects the mutually agreed commercial value of the transaction and is subject to appropriate fair value determination for accounting
purposes. This does not alter the number of shares or warrants to be issued as agreed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC BioPharma, Inc.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#34083;&#28113;&#40801;
    Shuling Jiang</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signature/Seal</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized Signature/Seal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name&#65306;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Uttam Yashwant Patil</I></FONT></TD>
    <TD STYLE="text-align: justify; width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name&#65306;</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shuling Jiang</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Land Owner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>abvc-20240208.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWayPaaPtyJ1xmYkxuG9yfTlK/yIvkBIzWC2ZSNvGIa8L -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ABVC="http://abvcpharma.com/20240208" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20240208">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240208_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240208_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>abvc-20240208_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>abvc-20240208_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="abvc-20240208.xsd#Cover" roleURI="http://abvcpharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">As previously reported,
on February 6, 2024, ABVC BioPharma, Inc. (the &#8220;Company&#8221;) reported that it entered into a definitive agreement
with Shuling Jiang (&#8220;Jiang&#8221;), pursuant to which Jiang shall transfer the ownership of certain land she owns
located at Taoyuan City, Taiwan (the &#8220;Land&#8221;) to the Company (the &#8220;Original Agreement&#8221;). Jiang
is a director of the Company, is married to TS Jiang, the Company&#8217;s Chief Strategic Office and currently owns approximately
8.16% of the Company&#8217;s issued and outstanding shares of the Company&#8217;s common stock, par value, $0.001 per share (the
&#8220;Comon Stock&#8221;). Accordingly, the transaction contemplated by the Agreement constitutes a related party
transaction as defined by Item&#160;404&#160;of&#160;Regulation S-K.

&#160;

As later reported, on
May 16, 2024, the Company&#8217;s board of directors determined that it was in the best interest of the Company and its shareholders
to terminate the Agreement and not proceed with the transfer of land ownership at such time and that it may later reconsider the
transaction.

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0249475-8ka_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvc-20240208.xsd</File>
    <File>abvc-20240208_lab.xml</File>
    <File>abvc-20240208_pre.xml</File>
    <File doctype="8-K/A" isOnlyDei="true" isUsgaap="true" original="ea0249475-8ka_abvcbio.htm">ea0249475-8ka_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0249475-8ka_abvcbio.htm": {
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20240208",
   "dts": {
    "schema": {
     "local": [
      "abvc-20240208.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20240208_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20240208_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0249475-8ka_abvcbio.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://abvcpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249475-8ka_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249475-8ka_abvcbio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-25-065728-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-065728-xbrl.zip
M4$L#!!0    ( (:(\EK=E?]E*P,  .@+   1    86)V8RTR,#(T,#(P."YX
M<V2U5MMRVC 0?>],_T'UNQ&&)@T$DDG()$-+TDS(_:4C;!DTD25'DL'TZROY
MQL5 @+9^DG?/.;LK[<ING<8!!6,L).&L;3F5J@4P<[E'V+!M/?3MLWZGV[7
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M.4[_G3QWGHC;Q5[PL!JV0M)2AH>*S5X?,&4,$D$^3JPK7.4-#>NK9%JYNU>
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M *+#G%Y_;(]N,;"\P6 \H7-B%D)M 0,(O3#3&("1'X)R"8!N D"$Y! F&]$
M&8NK+9LD)_U4CEBX/BN^/>>%.<7DOF$YO@SVD=P7H'*FFJC^%^LRIRW%XY1V
MQ0@EBYW$I0--VPY!M79G3$!.&1-U&G. U==)T-H '"Q,(7\,;4:JT3T&F?T(
MW@N0-D*I#-K29,T\STI#-0:>!MZQ6=\).!7AE.!%8-Y8G48&\2K!4^0J(B&!
MH-HAXC"PXDL5$4?\*%531#TT6F3LA#!AG0EER*5,4533.DJ,+&[49CK=";V4
M#I\GC9Q*5UT+E5@R,1;8*[#0/AHL,-<0]D$P.H.=ACN#^55U2Y%:T\- 5J^*
MN:B";8"2Q$!HCM".3+P45R SNN/$=7R?XY9>K&8$*:!;: 41:Z*1P[M-!5D
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M9)'J=8)7<$E14JP1"QH9<1!YZ@^$WQ-]#1J** =B(W#Z<KM1!&NH66@/#^2
M%O??"GC(0;$"!9[5,")5^ER$;A)4+ 8)#1YOC 12IO&S&E@ZAZ!/R1"=1^&2
MU8J[NW%Z).G(I45Q.&0FEPD5X:C-L)N/*^A$NG?P&'"@?3;+BLY\%?0I784@
MB+FP&-.9Z'V0^+X'9G"%BYC86<7G:KIO-1U"C1[''9PH^9-R6./)(70#2[-$
MJ0TX=<$TCL#CN#RR%I'?FJCERSSJ$6WZ:(F]USPF6NA0;DMM ";1V4L[.:")
M/@1&+&GL96YFQ+T@C!5>-%4A]\KJ+Y!82KU&P\#!Z_@- 1 \08]1J4YV!2%
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M&SZ"8L#1Y90F_'=[>T,B\D6+O!%0^&)132[H?&,BL=2=S1L+4S-7[ W9QFH
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MI^>7;UYMM;?,]^O^V9G__LV:S'FH9_AH^UF^\@,11315$)+^TY:)I-[HQ@\
MI9)AJ5YK"-<M'VVC,W)ZA5I>OMK:SU5:OY'T^NIR5%1Z=T)C'BV.OM3YQE^
M(I7??^KMH33\K;^S@BJ?&]Z;N/3"H^N^_?W!\_;+@^[V]_LO.QW\"5_;G:Y5
MH?3;6,4IP3\WC^2&M79X-,,57G[$.3T\M)9H, 215&>200JAT?]*?'W5!/Z.
MIOM&^1+]N6]/_*'N>KRP>NA,'FC+^U7.T\SALS]@*"1YV]^_.#QHO^A^J]%R
M#0[^D J]\^-?M*8Q^4#5;(X$XQKJ!UA8Y]_LQERC_?:S;UXS&V/0/S/;/0J8
MCG!3^NA/6J-_O5QA?N?X"BOB)TH.#];T='#UQ EX;6;9,SS\027D TC_9SH
M!X4.P 6>QO[_KO@/_L(5_U,?FLK#9P__VHG]\R?X5U+^"U!+ 0(4 Q0    (
M (:(\EK=E?]E*P,  .@+   1              "  0    !A8G9C+3(P,C0P
M,C X+GAS9%!+ 0(4 Q0    ( (:(\EKP]-E6_0H  '^&   5
M  "  5H#  !A8G9C+3(P,C0P,C X7VQA8BYX;6Q02P$"% ,4    " "&B/):
M6-/KN5P'  #85P  %0              @ &*#@  86)V8RTR,#(T,#(P.%]P
M<F4N>&UL4$L! A0#%     @ AHCR6@6%RN"+'   ?Y,  !D
M ( !&18  &5A,#(T.30W-2TX:V%?86)V8V)I;RYH=&U02P$"% ,4    " "&
MB/):S)?:V]H4  "$?P  '0              @ ';,@  96$P,C0Y-#<U,#%E
M>#$P+3%?86)V8V)I;RYH=&U02P$"% ,4    " "'B/):3@GS*ZT)  #3,P
M'0              @ 'P1P  96$P,C0Y-#<U,#%E>#$P+3)?86)V8V)I;RYH
M=&U02P$"% ,4    " "'B/):T:)3Q-T-   L10  '               @ '8
M40  96$P,C0Y-#<U,#%E>#0M,5]A8G9C8FEO+FAT;5!+!08     !P ' .P!
(  #O7P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea0249475-8ka_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20240208.xsd" xlink:type="simple"/>
    <context id="AsOf2024-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-02-08" id="Fact000003">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-02-08" id="Fact000004">0001173313</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-02-08" id="Fact000009">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-02-08" id="Fact000010">2024-02-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-02-08" id="Fact000011">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-02-08" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-02-08" id="Fact000013">001-40700</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-02-08" id="Fact000014">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-02-08" id="Fact000015">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-02-08" id="Fact000016">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-02-08" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-02-08" id="Fact000018">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-02-08" id="Fact000019">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-02-08" id="Fact000020">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-02-08" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-02-08" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-02-08" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-02-08" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-02-08" id="Fact000025">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-02-08" id="Fact000026">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-02-08" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-02-08" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="AsOf2024-02-08" id="Fact000029">As previously reported,
on February 6, 2024, ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;) reported that it entered into a definitive agreement
with Shuling Jiang (&#x201c;Jiang&#x201d;), pursuant to which Jiang shall transfer the ownership of certain land she owns
located at Taoyuan City, Taiwan (the &#x201c;Land&#x201d;) to the Company (the &#x201c;Original Agreement&#x201d;). Jiang
is a director of the Company, is married to TS Jiang, the Company&#x2019;s Chief Strategic Office and currently owns approximately
8.16% of the Company&#x2019;s issued and outstanding shares of the Company&#x2019;s common stock, par value, $0.001 per share (the
&#x201c;Comon Stock&#x201d;). Accordingly, the transaction contemplated by the Agreement constitutes a related party
transaction as defined by Item&#160;404&#160;of&#160;Regulation S-K.

&#160;

As later reported, on
May 16, 2024, the Company&#x2019;s board of directors determined that it was in the best interest of the Company and its shareholders
to terminate the Agreement and not proceed with the transfer of land ownership at such time and that it may later reconsider the
transaction.

&#160;</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
